Figure 5.

Synergistic effects of BTK inhibitor and myddosome assembly inhibitor on ABC DLBCL cells. (A, B) OCI-LY10 cells were treated for 72 h with ibrutinib, ST2825 or both, at the indicated doses, followed by a WST-1 assay. Inhibition at varying dosimetry values for the inhibitor of BTK (ibrutinib) and MYD88 (ST2825) in OCI-LY10 cells is depicted with (A) heat maps and (B) line graphs. (C) Synergism was evaluated via CI analysis, and the CI values of OCI-LY10 cells at varying dosimetry values for ibrutinib and ST2825 are demonstrated via heat maps. (D) Relative NF-κB luciferase activity was measured, following treatment of the OCI-LY10 cells for 12 h with the indicated concentrations of ibrutinib, ST2825 or both. Statistical analysis by one-way ANOVA and Tukey's post hoc test. Data are presented as the mean ± standard error of the mean from three independent experiments. **P<0.01. BTK, Bruton's tyrosine kinase; ABC, activated B cell; DLBCA, diffuse large B-cell lymphoma; MYD88, myeloid differentiation primary response gene 88; CI, combination index; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells.